Drug intelligence / Profile preview

ketamine + midazolam

Development stage: Unknown
Lead developer: Melt Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

ketamine + midazolam is a combination therapy being evaluated by Inonu University for its efficacy in reducing postpartum depression and managing postoperative pain in patients undergoing Cesarean section under spinal anesthesia. Ketamine acts as a non-competitive NMDA receptor antagonist, providing rapid antidepressant and analgesic effects. Midazolam, a short-acting benzodiazepine, acts as a positive allosteric modulator of the GABA-A receptor and is included in the regimen to provide sedation and mitigate potential psychomimetic side effects associated with ketamine, such as hallucinations and delirium.

Other names: ketamine and midazolam

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on ketamine + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + midazolam.

Explore the full profile